Search results
Results from the WOW.Com Content Network
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
(Reuters) -Moderna said on Friday the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer and BioNTech.
BNT162b2 was the code name during development and testing, [48] [58] tozinameran is the international nonproprietary name (INN), [40] [316] and Comirnaty is the brand name. [ 43 ] [ 2 ] According to BioNTech, the name Comirnaty "represents a combination of the terms COVID‑19, mRNA, community, and immunity".
Moderna Inc (NASDAQ: MRNA) reported mixed quarterly results Thursday and suggested an interim efficacy readout from the Phase 3 study is likely in November.The Moderna Bull Case: Moderna's vaccine ...
Moderna is on its way to getting a third mRNA-based vaccine approved by the FDA if the regulatory agency likes the data released Monday for a combination flu-COVID shot.The company said the new ...
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal. Pfizer and ...
For premium support please call: 800-290-4726 more ways to reach us
Waning demand for COVID vaccines and anticipation of a loss for 2023 led to a steep decline in Moderna's shares last year. Moderna posted a profit of $217 million, or 55 cents a share, for the ...